Home / Health / Lilly Drug Retatrutide Tops Ozempic in Diabetes Trial
Lilly Drug Retatrutide Tops Ozempic in Diabetes Trial
28 Oct
Summary
- Retatrutide showed superior blood sugar control compared to Ozempic.
- The experimental drug resulted in more than double the weight loss.
- A head-to-head trial compared doses of retatrutide against Ozempic.
In a significant development for type 2 diabetes management, Eli Lilly's experimental drug retatrutide has shown promising results in a comparative study.
Published on October 28, 2026, the trial revealed that retatrutide outperformed a lower-dose version of Novo Nordisk's Ozempic.
The study specifically compared 9 mg and 12 mg doses of Lilly's retatrutide against a 2 mg dose of Ozempic. The findings indicated that retatrutide achieved superior blood sugar control.
Furthermore, the experimental drug demonstrated a remarkable outcome in weight management, leading to more than double the weight loss observed with Ozempic. These results position retatrutide as a potential breakthrough therapy.
